Athira Pharma, Inc. (NASDAQ:LONA) Stock Has Average Price Target of $17.33 According to Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $17.33.

A number of equities analysts have recently commented on LONA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Friday, August 7th. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a research note on Saturday, October 17th. Citizens Jmp dropped their price objective on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a report on Monday, August 17th. Finally, Mizuho dropped their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, August 19th.

Athira Pharma Trading Up 1.4%

Shares of LONA stock opened at $4.96 on Friday. The firm’s 50 day moving average is $6.17 and its 200 day moving average is $7.59. The stock has a market capitalization of $46.59 million, a P/E ratio of -1.18 and a beta of 2.11. Athira Pharma has a 12 month low of $2.21 and a 12 month high of $14.21.

Athira Pharma (NASDAQ:LONA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). On average, equities analysts predict that Athira Pharma will post -2.67 EPS for the current year.

Athira Pharma Company Profile

Athira Pharma is a clinical-stage biotechnology company focused on developing regenerative therapies for neurodegenerative diseases. Its research has centered on treatments intended to activate the hepatocyte growth factor pathway, which may support neuronal health, repair, and regeneration.

The company’s lead investigational product is fosgonimeton, formerly known as ATH-1017, an intravenous therapy developed for potential use in Alzheimer’s disease and other neurodegenerative conditions.